T. Rowe Price Associates’s Arcutis Biotherapeutics ARQT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$10.6M Sell
448,207
-718,141
-62% -$18.3M ﹤0.01% 1205
2025
Q4
$33.9M Buy
1,166,348
+1,078,546
+1,228% +$27.6M ﹤0.01% 930
2025
Q3
$1.66M Buy
87,802
+3,755
+4% +$59.2K ﹤0.01% 1819
2025
Q2
$1.18M Buy
84,047
+6,107
+8% +$85.6K ﹤0.01% 1908
2025
Q1
$1.22M Buy
77,940
+35,591
+84% +$501K ﹤0.01% 1854
2024
Q4
$590K Sell
42,349
-17,799
-30% -$195K ﹤0.01% 2218
2024
Q3
$560K Buy
60,148
+1,246
+2% +$12.3K ﹤0.01% 2203
2024
Q2
$548K Buy
58,902
+11,149
+23% +$101K ﹤0.01% 2156
2024
Q1
$474K Buy
47,753
+1,681
+4% +$12.5K ﹤0.01% 2232
2023
Q4
$149K Buy
46,072
+23,125
+101% +$62.9K ﹤0.01% 2630
2023
Q3
$122K Buy
22,947
+622
+3% +$5.29K ﹤0.01% 2625
2023
Q2
$213K Buy
22,325
+2,560
+13% +$28.4K ﹤0.01% 2505
2023
Q1
$218K Buy
19,765
+519
+3% +$7.51K ﹤0.01% 2485
2022
Q4
$285K Sell
19,246
-160,048
-89% -$2.8M ﹤0.01% 2389
2022
Q3
$3.43M Sell
179,294
-273,763
-60% -$6.2M ﹤0.01% 1277
2022
Q2
$9.65M Buy
453,057
+4,355
+1% +$89.3K ﹤0.01% 1323
2022
Q1
$8.64M Sell
448,702
-374,466
-45% -$6.33M ﹤0.01% 1387
2021
Q4
$17.1M Buy
823,168
+9,474
+1% +$189K ﹤0.01% 1320
2021
Q3
$19.4M Sell
813,694
-111,264
-12% -$2.54M ﹤0.01% 1304
2021
Q2
$25.2M Buy
924,958
+268,537
+41% +$7.56M ﹤0.01% 1241
2021
Q1
$19M Buy
656,421
+393,640
+150% +$12.3M ﹤0.01% 1286
2020
Q4
$7.39M Sell
262,781
-728,240
-73% -$17.8M ﹤0.01% 1390
2020
Q3
$29M Sell
991,021
-75,519
-7% -$2.02M ﹤0.01% 1044
2020
Q2
$32.3M Buy
1,066,540
+85,926
+9% +$2.48M ﹤0.01% 992
2020
Q1
$29.2M Buy
+980,614
New +$26.3M ﹤0.01% 951

Other funds holding ARQT